Mills, Matthew N.
Figura, Nicholas B.
Arrington, John A.
Yu, Hsiang-Hsuan Michael
Etame, Arnold B.
Vogelbaum, Michael A.
Soliman, Hatem
Czerniecki, Brian J.
Forsyth, Peter A.
Han, Hyo S.
Ahmed, Kamran A. http://orcid.org/0000-0003-3331-1529
Article History
Received: 28 October 2019
Accepted: 30 January 2020
First Online: 6 February 2020
Compliance with ethical standards
:
: Hsiang-Hsuan Michael Yu has received spearker’s honoraria from BrainLab and is on the advisory boards of Novocure and Abbvie. Michael A. Vogelbaum has indirect equity and royalty interests in Infuseon Therapeutics, Inc. and has received honoraria from Tocagen, Inc. and Celgene. Hatem Soliman serves as a consultant for Astrazeneca, Celgene, Novartis, PUMA, and Eisai. Brian J. Czerniecki has intellectual property on a HER2 dendritic cell vaccine. Peter A. Forsyth has received research funding from Pfizer and Celgene and is on the advisory boards of Novocure, BTG, Inovio, AbbVie, Ziopharm, Tocagen, and Pfizer. Hyo S. Han declares that she has received a speaker’s honorarium from Lilly Pharmaceuticals, research funding to the institution from Abbvie, Tesaro, TapImmune, Novartis, Bristol-Myers Squibb, Pfizer, SeattleGenetics, Prescient, Horizon, and Karyopharm. Kamran A. Ahmed has received research funding from Bristol-Myers Squibb and Genentech.
: This article does not contain any studies with human participants or animals performed by any of the authors.